BioLineRX Ltd (BLRX) is a publicly traded Healthcare sector company. As of July 8, 2026, BLRX trades at $2.84 with a market cap of $13.74M and a P/E ratio of 0.00. BLRX moved +0.00% today. Year to date, BLRX is +10.00%; over the trailing twelve months it is -26.92%. Its 52-week range spans $2.15 to $22.60. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces BLRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioLineRx Shows GLIX1 Plus Olaparib Matches Cisplatin Efficacy in Ovarian Cancer Model: In a six-arm patient-derived ovarian cancer xenograft model, low-dose GLIX1 plus olaparib matched cisplatin’s tumor reduction and outperformed each monotherapy at optimal doses. Findings of strong synthetic lethality in homologous recombination–proficient tumors support adding an ovarian cancer cohort to BioLineRx’s Phase 1/2a GLIX1 trial.
| Metric | Value |
|---|---|
| Price | $2.84 |
| Market Cap | $13.74M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.60 |
| 52-Week Low | $2.15 |
| Volume | 198.90K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover BLRX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.